Braf V600E mutation in melanoma: translational current scenario

被引：0
作者：
J. A. Guadarrama-Orozco
A. Ortega-Gómez
E. B. Ruiz-García
H. Astudillo-de la Vega
A. Meneses-García
C. Lopez-Camarillo
机构：
[1] National Cancer Institute,Translational Medicine Laboratory
[2] Medical Center Siglo XXI,Laboratory of Translational Cancer Research and Cellular Therapy, Oncology Hospital
[3] National Cancer Institute,Genomics Sciences Program
[4] Autonomous University of Mexico City,undefined
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Melanoma; BRAF; V600E; Inhibitor resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50–60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.
引用
收藏
页码：863 / 871
页数：8
相关论文
共 61 条
[11]  
Wellbrock C(2010)Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 596-1703
[12]  
Karasaridis M(2013)MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Lancet Oncol. 14 249-undefined
[13]  
Marais R(2010)Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K Cancer Cell 18 683-undefined
[14]  
Kumar R(2012)Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 1694-undefined
[15]  
Angelini S(undefined)undefined undefined undefined undefined-undefined
[16]  
Czene K(undefined)undefined undefined undefined undefined-undefined
[17]  
Sauroja I(undefined)undefined undefined undefined undefined-undefined
[18]  
Balint B(undefined)undefined undefined undefined undefined-undefined
[19]  
van den Hurk K(undefined)undefined undefined undefined undefined-undefined
[20]  
Toomey S(undefined)undefined undefined undefined undefined-undefined
1234567